Categories Earnings, Other Industries

Valeant Pharmaceuticals International Inc. Q4 2017 earnings snapshot

Canada’s Valeant Pharmaceuticals posted a 9.9% decline in its fourth quarter 2017 revenue, driven by the impact of divestitures and lower volumes in the U.S. Diversified Products segment. Revenue declined to $2.16 billion from $2.4 billion in the second quarter of 2016.

The company swung to profit in the quarter compared to a loss a year ago, helped by increase in the benefit from income taxes. Net income attributable to Valeant was $513 million compared to a loss of $515 million in the same period in 2016.

Outlook

For the full year 2018, Valeant Pharmaceuticals expects revenues in the range of $8.10 billion to  $8.30 billion, while full year adjusted EBITDA is expected in the range of $3.05 billion to $3.20 billion. Valeant will continue to address its debt, as well as reduce expenses as it has been doing since first quarter of 2016, said the CEO Joseph Papa.

Valeant Pharmaceuticals fourth quarter 2017 earnings results

Most Popular

Key highlights from Autodesk (ADSK) Q4 2021 earnings results

Autodesk, Inc. (NASDAQ: ADSK) today reported its fourth quarter financial results for the period ended January 31, 2021. Net income for the fourth quarter was $911.3 million, or $4.10 per

Infographic: Beyond Meat (BYND) reports wider Q4 loss; Revenue up 4%

Beyond Meat (NASDAQ: BYND), a specialist in plant-based meat substitutes, Thursday reported a wider loss for the fourth quarter, despite an increase in revenues. The numbers also missed the consensus

Virgin Galactic stock tanks on delayed test flight

Virgin Galactic (NYSE: SPCE) reported fourth-quarter 2020 financial results after the regular market hours on Thursday. The space tourism company reported zero revenue in the fourth quarter, compared to $529,000

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top